Home › Companies › MARINUS PHARMACEUTICALS INC. › 2023-2024

MARINUS PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and MARINUS PHARMACEUTICALS INC.’s Form 8-K, filed 2024-05-24 (Item 5.07 on EDGAR). Page generated 04 October 2026.

7Reported items
121Asset managers
787Fund votes
2024-05-22Meeting date

Proxy season: 2023-2024

Explore MARINUS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by MARINUS PHARMACEUTICALS INC.

These tallies are MARINUS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-05-24 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

MARINUS PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2024-05-22
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Elan Ezickson	33,666,008	--	--	10,969,840	5,549,319	Majority: yes
Elect Director: Charles Austin	39,874,244	--	--	4,761,604	5,549,319	Majority: yes
Elect Director: Marvin H Johnson, Jr.	39,924,208	--	--	4,711,640	5,549,319	Majority: yes
Proposal 2: Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024	50,133,065	42,477	9,625	--	--	Majority: yes
Proposal 3: Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement	34,529,488	9,940,832	165,528	--	5,549,319	Majority: yes
Proposal 4: Approval of the 2024 Plan	32,505,734	11,953,605	176,509	--	5,549,319	Majority: yes

Source: MARINUS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-05-24 — read the filing on EDGAR.

How asset managers voted at the MARINUS PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 121 asset managers that disclosed a MARINUS PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of MARINUS PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 10 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%AGAINST 22%

FOR: 34,529,488AGAINST: 9,940,832

MARINUS PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement”): 34,529,488 for, 9,940,832 against, per its Form 8-K filed 2024-05-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,933,774 outstanding shares: 63% for, 18% against (81% of the company cast a for/against vote).

The 121 asset managers below cast 71% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 71%AGAINST 29%

FOR: 70.9%AGAINST: 28.8%ABSTAIN: 0.3%

Largest asset managers voting on “Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as di” at MARINUS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
SUVRETTA CAPITAL MANAGEMENT, LLC	4,608,520	0	For
Avoro Capital Advisors LLC	3,554,630	0	For
FRANKLIN ADVISERS INC	0	3,493,143	Against
JENNISON ASSOCIATES LLC	0	2,965,882	Against
BlackRock	2,871,052	0	For
Vanguard	2,788,356	0	For
MUTUAL FUND SERIES TRUST	2,709,800	0	For
Cormorant Asset Management, LP	2,499,602	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	2,331,250	0	For
Prudential/PGIM	385,000	1,730,518	Against
Bleichroeder LP	1,832,686	0	For
GMT CAPITAL CORP	0	1,625,078	Against
Bain Capital Life Sciences Investors, LLC	1,393,380	0	For
FRANKLIN STRATEGIC SERIES	0	1,200,781	Against
Aberdeen	0	1,105,144	Against
Woodline Partners LP	1,025,429	0	For
Citadel	854,558	0	For
Sofinnova Investments, Inc.	838,303	0	For
State Street	682,469	0	For
Point72	480,798	0	For
BALYASNY ASSET MANAGEMENT L.P.	0	451,331	Against
Victory Capital	432,862	0	For
GEODE CAPITAL MANAGEMENT, LLC	413,466	0	For
Ally Bridge Group (NY) LLC	394,773	0	For
Fidelity	390,974	0	For

Showing the 25 largest of 121 asset managers. See all 121 in the interactive database.

2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 50,133,065AGAINST: 42,477

MARINUS PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 50,133,065 for, 42,477 against, per its Form 8-K filed 2024-05-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,933,774 outstanding shares: 91% for, 0.1% against (91% of the company cast a for/against vote).

The 43 asset managers below cast 100% of the shares they voted on this item FOR (11,768,665 for, 0 against).

FOR 100%

FOR: 11,768,665 (100.0%)

Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting” at MARINUS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Vote
MUTUAL FUND SERIES TRUST	2,709,800	For
Vanguard	2,694,934	For
Prudential/PGIM	1,726,388	For
FRANKLIN STRATEGIC SERIES	1,200,781	For
BlackRock	1,114,847	For
Aberdeen	552,572	For
Fidelity	390,109	For
Altium Capital Management LP	219,586	For
Victory Capital	206,156	For
Charles Schwab	154,667	For
Simplify Exchange Traded Funds	150,000	For
Equitable	130,170	For
TIAA	126,977	For
QUANTITATIVE MASTER SERIES LLC	89,909	For
Lincoln Financial	41,700	For
Global X	24,081	For
Northern Trust	22,786	For
ProShares	20,573	For
John Hancock	20,046	For
Pacific Life	18,477	For
New York Life	17,664	For
Voya	17,045	For
State Street	15,678	For
MASTER INVESTMENT PORTFOLIO	14,038	For
Bridge Builder Trust	10,545	For

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

3. Approval of the Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan.

COMPENSATIONMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%AGAINST 27%

FOR: 32,505,734AGAINST: 11,953,605

MARINUS PHARMACEUTICALS INC.’s own tally for this item (“Proposal 4: Approval of the 2024 Plan”): 32,505,734 for, 11,953,605 against, per its Form 8-K filed 2024-05-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,933,774 outstanding shares: 59% for, 22% against (81% of the company cast a for/against vote).

The 42 asset managers below cast 75% of the shares they voted on this item FOR (8,761,282 for, 2,857,383 against).

FOR 75%AGAINST 25%

FOR: 8,761,282 (75.4%)AGAINST: 2,857,383 (24.6%)

Largest asset managers voting on “Approval of the Marinus Pharmaceuticals, Inc. 2024 Equity Incentive Plan.” at MARINUS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
MUTUAL FUND SERIES TRUST	2,709,800	0	For
Vanguard	2,694,934	0	For
Prudential/PGIM	0	1,726,388	Against
FRANKLIN STRATEGIC SERIES	1,200,781	0	For
BlackRock	1,114,847	0	For
Aberdeen	0	552,572	Against
Fidelity	390,109	0	For
Altium Capital Management LP	219,586	0	For
Victory Capital	0	206,156	Against
Charles Schwab	154,667	0	For
Equitable	88,870	41,300	For
TIAA	0	126,977	Against
QUANTITATIVE MASTER SERIES LLC	89,909	0	For
Lincoln Financial	0	41,700	Against
Global X	24,081	0	For
Northern Trust	0	22,786	Against
ProShares	0	20,573	Against
John Hancock	0	20,046	Against
Pacific Life	18,477	0	For
New York Life	17,664	0	For
Voya	0	17,045	Against
State Street	25	15,653	Against
MASTER INVESTMENT PORTFOLIO	14,038	0	For
Bridge Builder Trust	10,545	0	For
AQR	0	9,999	Against

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

4. Election of three Class I Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified: Charles Austin

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 39,874,244WITHHELD: 4,761,604

MARINUS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Charles Austin”): 39,874,244 for, 4,761,604 withheld, per its Form 8-K filed 2024-05-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,933,774 outstanding shares: 73% for, 9% withheld (81% of the company cast a for/withheld vote).

The 42 asset managers below cast 100% of the shares they voted on this item FOR (11,618,658 for, 0 against).

FOR 99.9%

FOR: 11,618,658 (100.0%)ABSTAIN: 7 (0.0%)

Largest asset managers voting on “Election of three Class I Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders or ” at MARINUS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
MUTUAL FUND SERIES TRUST	2,709,800	0	For
Vanguard	2,694,934	0	For
Prudential/PGIM	1,726,388	0	For
FRANKLIN STRATEGIC SERIES	1,200,781	0	For
BlackRock	1,114,847	0	For
Aberdeen	552,572	0	For
Fidelity	390,109	0	For
Altium Capital Management LP	219,586	0	For
Victory Capital	206,156	0	For
Charles Schwab	154,667	0	For
Equitable	130,170	0	For
TIAA	126,977	0	For
QUANTITATIVE MASTER SERIES LLC	89,909	0	For
Lincoln Financial	41,700	0	For
Global X	24,081	0	For
Northern Trust	22,786	0	For
ProShares	20,573	0	For
John Hancock	20,046	0	For
Pacific Life	18,477	0	For
New York Life	17,664	0	For
Voya	17,045	0	For
State Street	15,671	7	For
MASTER INVESTMENT PORTFOLIO	14,038	0	For
Bridge Builder Trust	10,545	0	For
AQR	9,999	0	For

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

5. Election of three Class I Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified: Elan Ezickson

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

75% Majority: yes · of votes cast

FOR 75%WITHHELD 25%

FOR: 33,666,008WITHHELD: 10,969,840

MARINUS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Elan Ezickson”): 33,666,008 for, 10,969,840 withheld, per its Form 8-K filed 2024-05-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,933,774 outstanding shares: 61% for, 20% withheld (81% of the company cast a for/withheld vote).

The 42 asset managers below cast 99.9% of the shares they voted on this item FOR (10,743,110 for, 374 against).

FOR 92%8%

FOR: 10,743,110 (92.5%)AGAINST: 374 (0.0%)ABSTAIN: 875,181 (7.5%)

Largest asset managers voting on “Election of three Class I Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders or ” at MARINUS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
MUTUAL FUND SERIES TRUST	2,709,800	0	For
Vanguard	2,694,934	0	For
Prudential/PGIM	1,726,388	0	For
FRANKLIN STRATEGIC SERIES	1,200,781	0	For
BlackRock	1,114,847	0	For
Aberdeen	0	552,572	Abstain
Fidelity	390,109	0	For
Altium Capital Management LP	219,586	0	For
Victory Capital	0	206,156	Abstain
Charles Schwab	154,667	0	For
Equitable	130,170	0	For
TIAA	126,977	0	For
QUANTITATIVE MASTER SERIES LLC	89,909	0	For
Lincoln Financial	41,700	0	For
Global X	24,081	0	For
Northern Trust	22,786	0	For
ProShares	0	20,573	Abstain
John Hancock	0	20,046	Abstain
Pacific Life	18,477	0	For
New York Life	17,664	0	For
Voya	0	17,045	Abstain
State Street	15,593	85	For
MASTER INVESTMENT PORTFOLIO	14,038	0	For
Bridge Builder Trust	10,545	0	For
AQR	0	9,999	Abstain

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

6. Election of three Class I Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified: Marvin H. Johnson, Jr.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 39,924,208WITHHELD: 4,711,640

MARINUS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Marvin H Johnson, Jr.”): 39,924,208 for, 4,711,640 withheld, per its Form 8-K filed 2024-05-24 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 54,933,774 outstanding shares: 73% for, 9% withheld (81% of the company cast a for/withheld vote).

The 42 asset managers below cast 100% of the shares they voted on this item FOR (11,618,661 for, 0 against).

FOR 99.9%

FOR: 11,618,661 (100.0%)ABSTAIN: 4 (0.0%)

Largest asset managers voting on “Election of three Class I Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders or ” at MARINUS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
MUTUAL FUND SERIES TRUST	2,709,800	0	For
Vanguard	2,694,934	0	For
Prudential/PGIM	1,726,388	0	For
FRANKLIN STRATEGIC SERIES	1,200,781	0	For
BlackRock	1,114,847	0	For
Aberdeen	552,572	0	For
Fidelity	390,109	0	For
Altium Capital Management LP	219,586	0	For
Victory Capital	206,156	0	For
Charles Schwab	154,667	0	For
Equitable	130,170	0	For
TIAA	126,977	0	For
QUANTITATIVE MASTER SERIES LLC	89,909	0	For
Lincoln Financial	41,700	0	For
Global X	24,081	0	For
Northern Trust	22,786	0	For
ProShares	20,573	0	For
John Hancock	20,046	0	For
Pacific Life	18,477	0	For
New York Life	17,664	0	For
Voya	17,045	0	For
State Street	15,674	4	For
MASTER INVESTMENT PORTFOLIO	14,038	0	For
Bridge Builder Trust	10,545	0	For
AQR	9,999	0	For

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

7. Approve Stock Compensation Plan

COMPENSATIONSHAREHOLDER RIGHTS AND DEFENSESMajority of the votes cast: yes

73% Majority: yes · of votes cast

FOR 73%AGAINST 27%

FOR: 32,505,734AGAINST: 11,953,605

The 2 asset managers below cast 100% of the shares they voted on this item FOR (28,698 for, 0 against).

FOR 16%ABSTAIN 84%

FOR: 28,698 (16.1%)ABSTAIN: 150,000 (83.9%)

Largest asset managers voting on “Approve Stock Compensation Plan” at MARINUS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
Simplify Exchange Traded Funds	0	0	150,000	0	Abstain
GRIMES & COMPANY, INC.	28,698	0	0	0	For

Largest MARINUS PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked by the number of MARINUS PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 54,933,774 shares outstanding at the time of that meeting.

Top MARINUS PHARMACEUTICALS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	SUVRETTA CAPITAL MANAGEMENT, LLC	8.39%
2	Avoro Capital Advisors LLC	6.47%
3	FRANKLIN ADVISERS INC	6.36%
4	JENNISON ASSOCIATES LLC	5.40%
5	BlackRock	5.23%
6	Vanguard	5.08%
7	MUTUAL FUND SERIES TRUST	4.93%
8	Cormorant Asset Management, LP	4.55%
9	ADAGE CAPITAL PARTNERS GP, L.L.C.	4.24%
10	Prudential/PGIM	3.85%

Reported MARINUS PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

MARINUS PHARMACEUTICALS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Suvretta Capital Management, LLC	9.95%	DEF14A
Blackrock, Inc.	8.37%	DEF14A
Eventide Asset Management, LLC	8.25%	DEF14A
S	7.98%	13G
Franklin Resources, Inc.	6.98%	DEF14A
Franklin Templeton	6.36%	13F
Prudential Financial, Inc.	6.03%	DEF14A
Cormorant Global Healthcare Master Fund, LP	5.92%	DEF14A
Avoro Capital Advisors LLC	5.73%	DEF14A
Jennison Associates LLC	5.39%	DEF14A

Percentages above are of 54,933,774 shares outstanding, as reported by MARINUS PHARMACEUTICALS INC. on its Form 10-Q dated 2024-05-03 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from MARINUS PHARMACEUTICALS INC.’s 10-Q dated 2024-05-03. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At MARINUS PHARMACEUTICALS INC.'s shareholder meeting held 2024-05-22, in the 2023-2024 proxy season, 121 asset managers reported how they voted in their SEC Form N-PX filings, covering 787 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on a non-binding advisory basis, of the compensation of the Company's named executive… — FOR was 78% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: MARINUS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-05-24.

MARINUS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page).